Reports
Reports
Sale
Technological Advancements in Detection Methods
There is a notable trend towards the development and adoption of advanced detection and analysis technologies, such as next-generation sequencing (NGS), liquid biopsy, and bioinformatics. These technologies offer higher sensitivity and specificity in detecting cancer biomarkers, even at low concentrations or in early disease stages. The ability to identify biomarkers from non-invasive samples, like blood or urine, is particularly transformative, enabling earlier diagnosis and monitoring of cancer with minimal patient discomfort.
Integration of Biomarkers in Personalized Medicine
Personalized or precision medicine is becoming increasingly central to cancer treatment, with biomarkers playing a key role in tailoring therapy to individual patients. As a result, cancer biomarkers market demand is on a surge. Biomarkers are used to predict patient response to specific therapies, allowing for more targeted treatment plans that can improve outcomes and reduce side effects. This trend underscores the shift from a one-size-fits-all approach to a more customized strategy in oncology.
Rise in Immuno-Oncology Biomarkers
The success of immunotherapies in treating various cancers has led to a surge in research and development of immuno-oncology biomarkers. These biomarkers help identify patients who are most likely to benefit from immunotherapies and monitor their response to treatment. The exploration of novel immuno-oncology biomarkers is a significant trend, reflecting the growing importance of the immune system in cancer therapy.
Expanding Applications of Biomarkers
Beyond diagnosis and therapy selection, cancer biomarkers are increasingly used for risk assessment, prognosis, and monitoring disease recurrence. The cancer biomarkers market size is expected to grow with a growing preference to use biomarkers in cancer screening programs and identify individuals at high risk of developing cancer, enabling early intervention. Additionally, biomarkers are being explored in the context of predicting disease progression and monitoring patients post-treatment for any signs of relapse.
Collaborations and Partnerships
The field of cancer biomarkers is characterized by active collaborations and partnerships patients’ academic institutions, biotechnology companies, and pharmaceutical firms. These collaborations aim to accelerate the discovery of novel biomarkers, the development of diagnostic tests, and the integration of biomarkers into clinical practice. Such partnerships are crucial for pooling resources, expertise, and technologies to advance the application of biomarkers in oncology.
Cancer Biomarkers Market Trends
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cancer Biomarkers Market Overview
3.1 Global Cancer Biomarkers Market Historical Value (2017-2023)
3.2 Global Cancer Biomarkers Market Forecast Value (2024-2032)
4 Global Cancer Biomarkers Market Landscape*
4.1 Global Cancer Biomarkers: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cancer Biomarkers: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Applications
5 Global Cancer Biomarkers Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cancer Biomarkers Market Segmentation (2017-2032)
6.1 Global Cancer Biomarkers Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Protein Biomarkers
6.1.3 Genetic Biomarkers
6.1.4 Others
6.2 Global Cancer Biomarkers Market (2017-2032) by Cancer Type
6.2.1 Market Overview
6.2.2 Lung Cancer
6.2.3 Breast Cancer
6.2.4 Leukemia
6.2.5 Melanoma
6.2.6 Colorectal Cancer
6.2.7 Prostate Cancer
6.2.8 Others
6.3 Global Cancer Biomarkers Market (2017-2032) by Applications
6.3.1 Market Overview
6.3.2 Prognostics
6.3.3 Diagnostics
6.3.4 Research and Development
6.3.5 Others
6.4 Global Cancer Biomarkers Market (2017-2032) by Profiling Technology
6.4.1 Market Overview
6.4.2 Omics
6.4.3 Imaging
6.4.4 Immunoassay
6.4.5 Bioinformatics
6.4.6 Others
6.5 Global Cancer Biomarkers Market (2017-2032) by End-User
6.5.1 Market Overview
6.5.2 Pharmaceuticals and Biotechnology Companies
6.5.3 Diagnostics and Research Laboratories
6.5.4 Hospitals
6.5.5 Others
6.6 Global Cancer Biomarkers Market (2017-2032) by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Cancer Biomarkers Market (2017-2032)
7.1 North America Cancer Biomarkers Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Protein Biomarkers
7.1.3 Genetic Biomarkers
7.1.4 Others
7.2 North America Cancer Biomarkers Market (2017-2032) by Cancer Type
7.2.1 Market Overview
7.2.2 Lung
7.2.3 Breast
7.2.4 Leukemia
7.2.5 Melanoma
7.2.6 Colorectal
7.2.7 Prostate
7.2.8 Others
7.3 North America Cancer Biomarkers Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Cancer Biomarkers Market (2017-2032)
8.1 Europe Cancer Biomarkers Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Protein Biomarkers
8.1.3 Genetic Biomarkers
8.1.4 Others
8.2 Europe Cancer Biomarkers Market (2017-2032) by Cancer Type
8.2.1 Market Overview
8.2.2 Lung cancer
8.2.3 Breast cancer
8.2.4 Leukemia cancer
8.2.5 Melanoma
8.2.6 Colorectal
8.2.7 Prostate
8.2.8 Others
8.3 Europe Cancer Biomarkers Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Cancer Biomarkers Market (2017-2032)
9.1 Asia Pacific Cancer Biomarkers Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Protein Biomarkers
9.1.3 Genetic Biomarkers
9.1.4 Others
9.2 Asia Pacific Cancer Biomarkers Market (2017-2032) by Cancer Type
9.2.1 Market Overview
9.2.2 Lung cancer
9.2.3 Breast cancer
9.2.4 Leukemia cancer
9.2.5 Melanoma
9.2.6 Colorectal
9.2.7 Prostate
9.2.8 Others
9.3 Asia Pacific Cancer Biomarkers Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Cancer Biomarkers Market (2017-2032)
10.1 Latin America Cancer Biomarkers Market (2017-2032) by Type
10.1.1 Market Overview
10.1.2 Protein Biomarkers
10.1.3 Genetic Biomarkers
10.1.4 Others
10.2 Latin America Cancer Biomarkers Market (2017-2032) by Cancer Type
10.2.1 Market Overview
10.2.2 Lung cancer
10.2.3 Breast cancer
10.2.4 Leukemia cancer
10.2.5 Melanoma
10.2.6 Colorectal
10.2.7 Prostate
10.2.8 Others
10.3 Latin America Cancer Biomarkers Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Cancer Biomarkers Market (2017-2032)
11.1 Middle East and Africa Cancer Biomarkers Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Protein Biomarkers
11.1.3 Genetic Biomarkers
11.1.4 Others
11.2 Middle East and Africa Cancer Biomarkers Market (2017-2032) by Cancer Type
11.2.1 Market Overview
11.2.2 Lung cancer
11.2.3 Breast cancer
11.2.4 Leukemia cancer
11.2.5 Melanoma
11.2.6 Colorectal
11.2.7 Prostate
11.2.8 Others
11.3 Middle East and Africa Cancer Biomarkers Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Illumina, Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 F. Hoffmann-La Roche Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bio-Rad Laboratories, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Qiagen N.V.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Thermo Fisher Scientific Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Myriad Genetics, Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Siemens Healthcare Private Limited
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 PerkinElmer Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Bio-Techne
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Hologic, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Quest Diagnostics Clinical Laboratories, Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Charles River Laboratories
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
List not exhaustive
18 Global Cancer Biomarkers Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.